Large investment in Tyrol

Novartis continues to rely on Austria for the development and production of biopharmaceuticals. The company is investing € 75 million to expand biopharmaceutical development at its Schaftenau facility in Tyrol. In addition to the new plant for the technical development of biopharmaceuticals, a new pilot plant is emerging for so-called “medical devices” such as autoinjectors and pen injectors.

“Close to half of all newly approved drugs are biopharmaceuticals, and this is showing an upward trend. It comes as no surprise that these medicinal products are opening up new therapeutic alternatives to treat a large number of diseases,” explains Michael Kocher, Country President Novartis Austria. Tyrol is home to the Novartis competence centre for modern cell culture technology. The site covers the entire value chain for biopharmaceuticals, from the active ingredients to the finished drug, and thus plays a key role in the global production network of the company.

Go on reading and find out more about research and development in Austria!